Posts by: Jose Marques Lopes, PhD

News

Evaluating the lung area that is normal, or healthy, can help predict the survival of patients with combined pulmonary fibrosis and emphysema (CPFE) at the time of lung cancer ... Read more

January 9, 2019January 16, 2019

Phase 1 Study of Potential IPF Therapy, PLN-74809, Doses 1st Group, Pliant Says

News

A Phase 1 trial of an investigational treatment for idiopathic pulmonary fibrosis (IPF), PLN-74809, has dosed a first group of healthy participants, Pliant Therapeutics announced. PLN-74809, the company’s lead candidate, is a ... Read more

January 2, 2019January 3, 2019

Sustained-release Ofev Shows Better Absorption Over Soft Capsules, Study Suggests

News

Sustained-release capsules of Ofev (nintedanib), which is used to treat idiopathic pulmonary fibrosis (IPF), were better at reaching systemic circulation in the body than the current marketed formulation, according ... Read more

December 11, 2018December 19, 2018

Nasal Sampling May Be Fast and Noninvasive Way to Identify and Manage IPF, Study Suggests

News

The nasal epithelium of patients with idiopathic pulmonary fibrosis (IPF) shows different levels of gene expression implicated in inflammatory and immune responses than those without the disease, a study ... Read more

November 21, 2018November 21, 2018

Phase 1 Trial of IPF Candidate Therapy BBT-877 Planned for January

News

Bridge Biotherapeutics filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start a Phase 1 trial of its idiopathic pulmonary fibrosis (IPF) ... Read more

November 16, 2018November 26, 2018

Redx Pharma to Update on Potential IPF Therapy, Including Those with Advanced Disease

News

Redx Pharma announced it soon give an update on early work on a potentially new type of idiopathic pulmonary fibrosis (IPF) treatment, called RXC006, that may help patients with advanced ... Read more

September 19, 2018September 24, 2018

Esbriet Enables Stable Lung Function Over 2 Years in IPF Patients, Real-World Study Confirms

Esbriet, News

Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) leads to stable lung function over two years, according to a real-world study. The data matches previous results from Phase ... Read more

September 14, 2018September 17, 2018

FDA Puts FibroGen’s Pamrevlumab on Fast Track as IPF Treatment

News

FibroGen’s investigational compound pamrevlumab has received fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The agency’s decision follows review ... Read more

September 5, 2018September 10, 2018

Medicare Covers Veracyte’s Envisia Genomic Classifier Test for IPF Diagnosis

News

The Envisia Genomic Classifier test for idiopathic pulmonary fibrosis (IPF) diagnosis received a draft Medicare local coverage determination (LCD) through the MolDx (Molecular Diagnostics) service program, according to Veracyte. ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Size of Healthy Lung Area Can Help Predict Survival in CPFE Patients with Lung Cancer, Study Says

Phase 1 Study of Potential IPF Therapy, PLN-74809, Doses 1st Group, Pliant Says

Top 10 Pulmonary Fibrosis Stories of 2018

Sustained-release Ofev Shows Better Absorption Over Soft Capsules, Study Suggests

Nasal Sampling May Be Fast and Noninvasive Way to Identify and Manage IPF, Study Suggests

Phase 1 Trial of IPF Candidate Therapy BBT-877 Planned for January

Redx Pharma to Update on Potential IPF Therapy, Including Those with Advanced Disease

Esbriet Enables Stable Lung Function Over 2 Years in IPF Patients, Real-World Study Confirms

FDA Puts FibroGen’s Pamrevlumab on Fast Track as IPF Treatment

Medicare Covers Veracyte’s Envisia Genomic Classifier Test for IPF Diagnosis

Pin It on Pinterest